Thulium-170-Labeled Microparticles for Local Radiotherapy: Preliminary Studies

Polyák, András; Das, Tapas; Chakraborty, Sudipta; Király, Réka; Dabasi, Gabriella; Jóba, R. P.; Jakab, Csaba; Thuróczy, Julianna; Pöstényi, Zita; Haász, Veronika; Gergely, J; Jánoki, Győző A.; Pillai, M.R.A.

doi:10.1089/cbr.2014.1680

Cited by 11 publications

(10 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5. Production of 153 Sm and ingrowth of 154 Eu by irradiation of a highly enriched 152 Sm (98.70%) target using a thermal neutron flux of 3.5Á10 14 n cm À2 s À1 . Fig.…”

Section: Purification Processes For Reactor-produced Medical Radiolanthanidesmentioning

confidence: 99%

See 2 more Smart Citations

Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

Voorde

Hecke

Cardinaels

et al. 2019

Coordination Chemistry Reviews

View full text Add to dashboard Cite

“…5. Production of 153 Sm and ingrowth of 154 Eu by irradiation of a highly enriched 152 Sm (98.70%) target using a thermal neutron flux of 3.5Á10 14 n cm À2 s À1 . Fig.…”

Section: Purification Processes For Reactor-produced Medical Radiolanthanidesmentioning

confidence: 99%

“…Therefore, irradiation of a natural samarium target is not preferred. The isotopically enriched 152 Sm target Fig. 11.…”

Section: Samarium-153mentioning

confidence: 99%

See 1 more Smart Citation

Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

Voorde

Hecke

Cardinaels

et al. 2019

Coordination Chemistry Reviews

View full text Add to dashboard Cite

“…Similar clinical results are reported in horses, where a dose raging between 5 and 15 Gy has been used to treat degenerative joint diseases (DJD) ( 17 , 18 ). First experiences of local radiation therapy by intra-articular administration of β-emitting radionuclides are reported in dogs, showing improvement in clinical signs and no significant side effects ( 19 , 20 ). Recently, a single-fraction 10 Gy RT protocol has been investigated in five Labrador Retrievers affected by elbow OA, with short-term clinical benefit and improved weight bearing in the affected limb ( 21 ).…”

Section: Introductionmentioning

confidence: 99%

Megavoltage Radiotherapy for the Treatment of Degenerative Joint Disease in Dogs: Results of a Preliminary Experience in an Italian Radiotherapy Centre

et al. 2018

View full text Add to dashboard Cite

The aim of the study was to evaluate the efficacy and toxicity of a low-dose radiotherapy treatment in dogs with osteoarthritis (OA). Inclusion criteria were dogs affected by OA of one or multiple joints, with lameness, previously treated with medical therapy and referred for radiotherapy because of chronic unresponsive pain. After suspension of medical therapy, dogs underwent external beam radiotherapy treatments delivered in three fractions of 2 Gy each. Four of these dogs had one (three dogs) to four (one dog) additional courses of radiation. Medical records were reviewed and follow-up information was collected by clinical recheck and owners interview. Twenty-five dogs matched the inclusion criteria; among them, 21 had one course of RT and 4 underwent multiple treatments, respectively 218, 266, 39, and 1,384 days after the first treatment. Clinical improvement was observed in 92% of patients with median benefit duration of 356 days after the first treatment, and 418 days after the second treatment. No side effects were recorded. In this group of patients, radiotherapy was effective, well tolerated, and repeatable, leading to an improvement of quality of life in dogs with degenerative joint disease unresponsive to medical treatments.

show abstract

“…Radiolabeling examination was carried out on ZU particles ( 99m Tc-ZU) via a previously applied method. 34,35 Labeling efficiency of 99m Tc-ZU particles was checked by thin layer chromatography using ITLC-SG plates (Agilent Technologies) with MEK eluent. In order to verify in vivo particle size stability and 99m Tc-binding stability of the product, SPECT/CT imaging investigations were performed in a human SPECT/CT system (AnyScan, Mediso Ltd, HU).…”

mentioning

confidence: 99%

Inherently fluorescent and porous zirconia colloids: preparation, characterization and drug adsorption studies

et al. 2015

View full text Add to dashboard Cite

Porous, fluorescent zirconia particles of nearly 380 nm diameter were prepared without template molecules or labeling dyes. The porous structure is the result of aggregation-induced particle formation. The inherent fluorescence is assigned to coordinatively unsaturated Zr 4+ ions at the sol-gel derived ZrO 2 surface. After physico-chemical characterization of the native zirconia particles carboxyl and/or amine bearing drug molecules (D,L-a-difluoromethylornithine -DFMO, ursolic acid -UA and doxorubicin -DOX) were adsorbed onto their surface, and the products were analyzed with Fourier-transform infrared spectroscopy (FTIR), thermogravimetry (TG), small-angle X-ray scattering (SAXS), fluorimetry and zeta potential vs. pH measurements. We have found that DOX complexes coordinatively unsaturated Zr 4+ ions without dislocating them, while carboxyl-bearing drugs interact with basic surface Zr-OH sites eliminating some of the carbonate species. The adsorption of UA at the zirconia surface shifts considerably the isoelectric point of the surface and thus provides kinetic stability to the particles at physiological pH. An in vivo biodistribution study in two healthy dogs performed by SPECT/CT detection after 99mTc labeling of the nanocarriers has shown the possibility of drug delivery application. IntroductionNano-and microparticles of various kinds are currently investigated with the prospect of drug delivery application. The requirements to be fulfilled are numerous: drug carrier particles should encapsulate, transport and release drug molecules in a controlled way in living organism. 1 Multifunctionality is, therefore, inevitable and -when coupled to easy synthesisrepresents a great advantage. Among inorganic particles silica 2,3 is preferred for its controlled synthesis, low toxicity, established conjugation methods and high drug loading capacity (for mesoporous silica).Zirconia, a ceramic material, is used for biomedical applications e.g. in dental and chirurgical implants. [4][5][6] It is known to be biocompatible, and we have shown in our preliminary experiments that zirconia is also biodegradable under certain circumstances. The surface of zirconia is chemically active, having both acidic and basic sites. 7 This explains that zirconia chemisorbs both NH 3 and CO 2 . 8 Under ambient conditions, the zirconia surface is always covered by CO and CO 2 adsorbed from the air. 9,10 Complex formation has also been observed with the carboxyl groups of citric acid and poly-e-caprolactone. 11,12 As was observed by Pokrovski et al. CO 2 adsorption on monoclinic (m-) ZrO 2 is more than an order of magnitude higher than that on tetragonal (t-) ZrO 2 . 13 High-temperature synthesis or annealing of ZrO 2 leads to the transformation of the monoclinic phase into tetragonal. However, the lack of a generally approved synthetic method providing stable m-ZrO 2 colloid hinders its use as a drug carrier. Nanocrystalline powders of t-ZrO 2 are produced by aqueous phase reaction followed by annealing.14-17 These materials sintered by a fi...

show abstract

Thulium-170-Labeled Microparticles for Local Radiotherapy: Preliminary Studies

Cited by 11 publications

References 22 publications

Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications

Megavoltage Radiotherapy for the Treatment of Degenerative Joint Disease in Dogs: Results of a Preliminary Experience in an Italian Radiotherapy Centre

Inherently fluorescent and porous zirconia colloids: preparation, characterization and drug adsorption studies

Contact Info

Product

Resources

About